175 related articles for article (PubMed ID: 23774876)
1. Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents.
Ramanathan S; Mathias A; Wei X; Shen G; Koziara J; Cheng A; Kearney BP
J Acquir Immune Defic Syndr; 2013 Sep; 64(1):45-50. PubMed ID: 23774876
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and bioequivalence evaluation of single-tablet and separate-tablet regimens for once-daily cobicistat-boosted elvitegravir in healthy Japanese male subjects: A randomized, two-way crossover study.
Shiomi M; Matsuki S; Ikeda A; Ishikawa T; Nishino N; Kimura M; Kumagai Y; Irie S
Clin Pharmacol Drug Dev; 2015; 4(3):218-25. PubMed ID: 27140802
[TBL] [Abstract][Full Text] [Related]
4. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.
German P; Warren D; West S; Hui J; Kearney BP
J Acquir Immune Defic Syndr; 2010 Nov; 55(3):323-9. PubMed ID: 20683270
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Interactions Between the Fixed-Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult Participants.
Feng HP; Guo Z; Fandozzi C; Panebianco D; Caro L; Wolford D; Dreyer DP; Valesky R; Martinho M; Rizk ML; Iwamoto M; Yeh WW
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):952-961. PubMed ID: 31173673
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance.
Bruce RD; Winkle P; Custodio JM; Wei X; Rhee MS; Kearney BP; Ramanathan S; Friedland GH
Antimicrob Agents Chemother; 2013 Dec; 57(12):6154-7. PubMed ID: 24080665
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc.
Ramanathan S; Abel S; Tweedy S; West S; Hui J; Kearney BP
J Acquir Immune Defic Syndr; 2010 Feb; 53(2):209-14. PubMed ID: 19851115
[TBL] [Abstract][Full Text] [Related]
9. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
Gaur AH; Kizito H; Prasitsueubsai W; Rakhmanina N; Rassool M; Chakraborty R; Batra J; Kosalaraksa P; Luesomboon W; Porter D; Shao Y; Myers M; Ting L; SenGupta D; Quirk E; Rhee MS
Lancet HIV; 2016 Dec; 3(12):e561-e568. PubMed ID: 27765666
[TBL] [Abstract][Full Text] [Related]
10. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.
Kulkarni R; Abram ME; McColl DJ; Barnes T; Fordyce MW; Szwarcberg J; Cheng AK; Miller MD; White KL
HIV Clin Trials; 2014; 15(5):218-30. PubMed ID: 25350960
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment.
Bruce RD; Winkle P; Custodio JM; Wei LX; Rhee MS; Kearney BP; Ramanathan S; Friedland GH
J Acquir Immune Defic Syndr; 2013 Aug; 63(4):480-4. PubMed ID: 23599011
[TBL] [Abstract][Full Text] [Related]
12. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
[TBL] [Abstract][Full Text] [Related]
13. Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir.
Mathias AA; Hinkle J; Shen G; Enejosa J; Piliero PJ; Sekar V; Mack R; Tomaka F; Kearney BP
J Acquir Immune Defic Syndr; 2008 Oct; 49(2):156-62. PubMed ID: 18769354
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137.
Ramanathan S; Shen G; Cheng A; Kearney BP
J Acquir Immune Defic Syndr; 2007 Jul; 45(3):274-9. PubMed ID: 17414929
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetics of Boosted-Elvitegravir in HIV-Infected Patients.
Custodio JM; Gordi T; Zhong L; Ling KH; Ramanathan S
J Clin Pharmacol; 2016 Jun; 56(6):723-32. PubMed ID: 26449283
[TBL] [Abstract][Full Text] [Related]
16. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of boosted elvitegravir in subjects with hepatic impairment.
Custodio JM; Rhee M; Shen G; Ling KH; Kearney BP; Ramanathan S
Antimicrob Agents Chemother; 2014 May; 58(5):2564-9. PubMed ID: 24550332
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.
Ramanathan S; Custodio JM; Wei X; Wang H; Fordyce M; Dave A; Ling KH; Szwarcberg J; Kearney BP
J Acquir Immune Defic Syndr; 2016 Jul; 72(3):281-8. PubMed ID: 26885802
[TBL] [Abstract][Full Text] [Related]
19. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial.
Arribas JR; Pialoux G; Gathe J; Di Perri G; Reynes J; Tebas P; Nguyen T; Ebrahimi R; White K; Piontkowsky D
Lancet Infect Dis; 2014 Jul; 14(7):581-9. PubMed ID: 24908551
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
Inciarte A; Leal L; González E; León A; Lucero C; Mallolas J; Torres B; Laguno M; Rojas J; Martínez-Rebollar M; González-Cordón A; Cruceta A; Arnaiz JA; Gatell JM; García F;
J Antimicrob Chemother; 2017 Oct; 72(10):2857-2861. PubMed ID: 29091217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]